Computer vision, Parkinson’s disease, and the unfinished work of clinical translation

Movement disorders neurology remains an act of watching

Before a clinical encounter even formally begins, we neurologists watch a foot hesitate at a doorway, a stride shorten on the way to the chair, a subtle change in facial animation during a greeting. We watch for amplitude, speed, asymmetry, overflow, and the countless combinations thereof. We watch in the clinic, in corridors, sometimes as early as the waiting room. This observation fills many of our working hours. And yet, for all the advances in molecular imaging, genetics, fluid biomarkers and artificial intelligence, Parkinson’s disease is still often first recognised through this language of movement - in what the body does, how it does it, and what it no longer quite does.

Video has long been part of this practice, helping us teach, document, compare and remember¹. In their recent editorial in Brain, Ganos, Stanley and Lang argue that video in movement disorders is never just a recording – it is what shapes clinical representation, pedagogy and the visual norms through which human variation is understood. As such, it carries scientific value, but also moral weight: it documents disease, and it documents a person living with it².

Artificial intelligence has now arrived at the core of this visual tradition, offering tools that can document and measure movement from an ordinary video, including smartphone recordings, without expensive, complex hardware. Not long ago, this would have seemed an audacious prospect for a field so intimately linked to visual documentation. With the advent of convolutional neural networks, it has become a reality.

Computer vision promises to take what neurologists already do – carefully observe movement - and make it measurable, repeatable, and available beyond clinic walls and the constraints of tight schedules. In Parkinson’s disease, this is an attractive proposition: a disease that fluctuates over hours and days, and evolves over years, is still assessed largely through brief, artificial clinical encounters. We ask patients how they have been over weeks or months, then score a few minutes of performance under fluorescent lights, often at a time of day that may not represent their usual function - not to mention the “good day effect”. We know this practice is born of a lack of better tools, and that it is insufficient. Our patients know it too.

The literature gives reason for optimism. Recent reviews show that Parkinson’s disease is the most frequently studied movement disorder in computer vision research, that gait is the most common task and that diagnostic accuracies frequently exceed 80%³. Open-source and commercial platforms suggest the field is moving from bespoke engineering demonstrations toward shared clinical tools⁴. Several studies, many published in npj Parkinson’s Disease, have further shown that computer vision may inform both clinical decision-making and pathophysiological investigation of parkinsonian bradykinesia across body parts, therapy conditions and care settings^5–9. Beyond bradykinesia, computer vision has enabled video-based quantification of tremor amplitude and frequency, the pull test and facial expressivity, often with close agreement to reference methods such as motion capture and accelerometry^10–13. A camera in a clinic, home or aged-care facility, it seems, could soon reveal meaningful motor information without wires, markers or specialist hardware^3,14,15.

Yet the growing number of publications should not be confused with equivalent progress towards clinically valid digital biomarkers. Showing that an algorithm can distinguish patients from controls, reproduce a clinical score or perform well within a selected dataset is an important first step, but it is not sufficient. A video-derived measure intended for clinical use must undergo the same scrutiny as any other biomarker or clinical outcome measure: it should demonstrate test–retest reliability, acceptable measurement error, construct validity, responsiveness to clinically meaningful change and robustness across populations, recording environments and disease stages. Crucially, we need to understand whether a change in the output reflects a true change in the patient rather than variation in camera position, lighting, task execution or model performance. Without this deeper clinimetric work, technical accuracy can easily be mistaken for biological or clinical validity. This may be a reason why the field has produced many models and feasibility demonstrations, but comparatively few, if any, clinically mature digital biomarkers.

For all our fascination with these technological advances, and our desire to see them succeed, their potential is clear: better measurement, earlier detection, remote care, trial enrichment and more equitable access to specialist assessment. But realising that potential depends on addressing a pressing challenge: the translation of technical performance into valid measurement, clinical action and patient benefit.

Beyond practical issues such as who requests, analyses and interprets video outputs, harder questions follow. A 10% change in finger-tapping amplitude means little until we know what it means for someone’s daily life. Increasing sensitivity may also shift the boundaries of what we call “prodromal” or “pre-symptomatic”, raising questions about disclosure, follow-up, responsibility and reimbursement. Patients must be involved in deciding how they feel about being filmed for diagnosis or monitoring. And any tangible benefit must be legible to both patients and their physicians, not just to a model. These are the implementation questions that separate a research instrument from a clinical tool. Addressing them will require implementation science from the outset, including evaluation of acceptability, feasibility, workflow fit, equity, sustainability and unintended consequences across diverse care settings. For selected motor tasks and recording conditions, the question is no longer simply whether computer vision can extract accurate measures of parkinsonian movement. Increasingly, we know that it can. The more relevant question is whether it can also become useful and valuable.

A tool may be technically accurate and still be clinically irrelevant. It may correlate with a rating scale but fail to change a decision. It may add measurement without adding meaning. With the broad availability of wearable technology, medicine is generating a growing number of digital outcomes. Yet despite their technical validity, adoption in clinical studies and guidelines is very limited^16,17. For computer vision to avoid this fate, it must be built around defined clinical decisions and care pathways rather than computational possibility, with explainability taking centre stage. Explainability should be treated not as a cosmetic layer added after model development but as a clinical requirement test with its intended users. Parkinson’s care does not need more numbers in the abstract. It needs help with practical, complex questions - questions such as “Is levodopa still helping?”, “Is gait changing because of Parkinson’s disease, arthritis, cognition, pain or environment?” and “Is this treatment effect large enough to matter to the person living with the disease”?

There are harder questions still. If a computer vision algorithm detects deterioration before the patient does, but no effective intervention or care response is available, have we actually helped? Do patients even want this? If a model flags early Parkinson’s disease in someone not yet diagnosed, who carries responsibility for that knowledge?

The ethical risks extend beyond the misuse of video data. They include the danger that patients become increasingly visible to health systems without becoming meaningfully better supported by them. Surveillance without response is not care. If a system can detect falls risk, wearing-off, freezing or deterioration, it must be connected to a pathway for timely action. Without such a pathway, computer vision risks becoming a sophisticated way of exposing disease-related need, while leaving that need unmet.

This shifts the scientific goalposts away from technical benchmarks, bespoke coding-intensive solutions and clinically meaningless error metrics, and towards deployable, user-friendly and interpretable tools that generate outcomes of value to both doctors and patients. The value of such digital biomarkers extends beyond technical performance: it emerges from rigorous testing against the decisions and outcomes they are intended to inform. This aligns with the broader digital biomarker literature in Parkinson’s disease, which emphasises that digital measures require evidence of reliability, validity, interpretability, regulatory readiness and integration into care pathways before they can become clinically useful biomarkers¹⁸.

More speculatively, computer vision can also inspire us to reconsider how we visually assess our patients. If computer vision can quantify a clinical gesture such as finger tapping - traditionally just a proxy for disease severity - with this much nuance, should we not leverage that precision to measure real-world function directly, i.e. moving towards “ecologically valid neuroscience”? Or, what if a machine’s attention could teach our own, by pointing our eyes to the regions of a video frame it found most informative for a given clinical outcome?¹⁹ In both scenarios, explainability is paramount. Clinicians are more likely to trust and act on outputs that resemble clinical reasoning than “black-box” abstraction: a report visualising reduced amplitude, progressive decrement and increasing irregularity during finger tapping is more interpretable and likely more acceptable than an opaque probability derived from a model that clinicians struggle to understand, let alone explain to a patient. Such explanation must also be faithful to how the model reached its conclusion, rather than merely plausible visualisations generated after the event. The goal is not to replace the neurologist’s eye but to extend it - to slow it down, render it more quantitative and objective, and let it attend to moments it might have missed. This is the “discerning eye of computer vision”.

Future directions for computer vision should therefore be ambitious, but not naive. We can imagine movement vital signs: brief standardised videos captured at home or before clinic, summarising gait speed, turning, arm swing or facial expressivity. We can imagine remote specialist augmentation, which rural clinicians, aged-care staff or general neurologists capture structured video and receive an interpretable, clinically governed movement summary - not a diagnosis from a machine, but a better map for human care.

Other fields that have already travelled this path already offer us important lessons too. Radiology did not become digital simply because images could be processed; it built PACS, reporting standards, accreditation, quality assurance and clinical governance. Diabetes care did not integrate continuous glucose monitoring merely because glucose could be measured continuously; it became useful when patients, clinicians, devices, reimbursement systems and therapeutic algorithms converged around action. Aviation and other high-stakes contexts emphasise that automation becomes safe when embedded in systems that account for human behaviour, fatigue, error, accountability and trust. In this vein, we argue that the movement disorders field now needs its own infrastructure for visual, measurement-based medicine. That infrastructure must include not only technical standards, but implementation frameworks capable of identifying where, for whom and under what conditions computer vision adds value.

The next phase of computer vision in Parkinson’s disease should be defined not by the number of movements that can be extracted from video, but by the number of video-derived measures that withstand rigorous biomarker validation and improve a specified clinical decision. That demands three things. First, standards: consensus protocols for video acquisition, metadata, reporting and validation. Second, proof: prospective implementation studies testing whether computer vision changes clinical decisions, outcomes or patient experience, with outputs co-designed with clinicians, patients and carers, not just delivered to them. Third, governance: bias and failure-mode audits, regulatory and reimbursement pathways matched to real use cases, and explicit responsibility when systems fail or performance deteriorates. Across all three, explainability should be evaluated empirically: can intended user understand an output, recognise its uncertainty and determine what action, if any, should follow? Publication standards should rise accordingly: retrospective performance in a curated dataset should be considered an entry point, not an endpoint. Priority should shift toward studies establishing whether a computer vision-derived measure is reliable, responsive, reproducible, generalisable and clinically actionable.

Still, the most important future may be quieter than this: could computer vision help patients feel believed? Many people with Parkinson’s describe changes that are intermittent, subtle or hard to name. They know when walking has become subjectively less automatic, buttoning a shirt feels harder or medication subtly starts to wear off. A sensitive visual tool could make these experiences visible - not replacing the patient’s narrative, but standing alongside it. The measure of computer vision will not be merely its tracking accuracy, but whether it leaves the person in front of us better cared for - and, perhaps, better believed.

Now comes the harder work: making computer vision part of medicine, not merely part of research. Just as Parkinson’s disease alters movement in fractions, with a little less amplitude and a little more effort, computer vision allows us to measure those fractions earlier, more sensitively and more faithfully. As a community of clinicians, scientists and people with lived experience, we must now decide what this new way of seeing is for. Its future will be determined not by how precisely algorithms quantify movement, but by whether those measurements improve decisions, transform outcomes, and ultimately, help people with Parkinson’s disease live better lives.

Author contributions

J.A. and M.U.F. jointly conceived the editorial and wrote, reviewed, and approved the final manuscript.

Competing interests

J.A. reports payment from AbbVie Ltd, STADA Ltd, and Lilly Ltd for medical lectures; medical congress travel support from the Michael J Fox Foundation and Shake It Up; holds stocks as the unpaid Medical Advisor for ClearSky Medical Diagnostics, and receives royalties from CRC Publishing for authored medical textbooks. M.U.F. reports consulting fees from CereGate GmbH and Tovly LLC, outside of the submitted work. J.A. and M.U.F. serve as associate editors at npj Parkinson’s disease.